No Picture
Jobs

Research Technician – Charlestown, MA 02129

Profile insightsFind out how your skills align with the job descriptionSkillsDo you have experience in Research?EducationDo you have a Doctoral degree?   Research Technician – (3295307) GENERAL SUMMARY/ OVERVIEW STATEMENT: We are seeking a bright and motivated individual for a Research Technician I position in… Click here to view original post… […]

[adinserter block="3"]
News

Melmark Receives $30M Gift to Fuel Services for Individuals with Autism, Intellectual and Developmental Disabilities

Landmark contribution will have generational impact and accelerate the development of the EnvisionSMART™ Institute. BERWYN, Pa. and ANDOVER, Mass. and CHARLOTTE, N.C., June 24, 2024 /PRNewswire/ — Melmark, a nationally-recognized non-profit human services provider, announced that it has… … […]

News

Lykos’ pain is others’ gain as psychedelic biotechs take notes from adcomm vote

Lykos’ near-unanimous rejection from an FDA advisory panel earlier this month jolted a psychedelics industry that seemed to be finally hitting its stride. But the race to market is far from over. “Our phones have been ringing off the hook since [Lykos’] adcomm, with entities who maybe were less familiar… … […]

[adinserter block="3"]
News

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term CAMBRIDGE, Mass., June 24, 2024 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company… … […]

News

Alnylam Aces Phase III Cardio Trial, Eyes Label Expansion for RNAi Therapy

Pictured: Alnylam’s headquarters building in Massachusetts/iStock, hapabapa Alnylam Pharmaceuticals on Monday revealed topline data from the Phase III HELIOS-B study, showing that its RNAi therapy Amuvttra (vutrisiran) can significantly lower the risk of death and recurrent cardiovascular events in… … […]

No Picture
News

NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

$20 million upfront with up to an additional $50 million of aggregate gross proceeds upon the exercise in full of clinical milestone-linked Series Warrants are expected to provide cash runway to complete the Phase 1 Part 3 clinical trial CAMBRIDGE, Mass., June 24, 2024 /PRNewswire/ –… … […]

[adinserter block="3"]
No Picture
News

Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission

WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has reached alignment with the Food and Drug Administration (“FDA”) on its biologics license application (“BLA”) resubmission strategy for cosibelimab. Accordingly, Checkpoint plans to move… … […]